YM155 (sepantronium bromide) has been evaluated in clinical trials as a survivin suppressant, but despite positive signals from early work, later studies were negative. Clarification of the mechanism of action of YM155 is important for its further development. YM155 affects cells in a cell cycle-specific manner. When cells are in G1, YM155 prevented their progression through the S phase, leaving the cells at G1/S when exposed to YM155. Passage through mitosis from G2 is also defective following YM155 exposure. In this study, YM155 did not behave like a typical DNA intercalator in viscosity, circular dichroism, and absorption spectroscopy studies. In addition, molecular modeling experiments ruled out YM155 DNA interaction to produce DNA intercalation. We show that YM155 inhibited topoisomerase 2α decatenation and topoisomerase 1-mediated cleavage of DNA, suggesting that YM155 inhibits the enzyme function. Consistent with these findings, DNA double-strand break repair was also inhibited by YM155.
Introduction
Topoisomerases (TOPs) are enzymes that disentangle DNA during DNA replication, transcription, repair, and recombination processes [1] . TOP1 releases the supercoiling and torsional tension of DNA introduced during the DNA replication and transcription processes by transiently cleaving and rejoining a single strand of the DNA duplex, TOP2 catalyzes the breaking and rejoining of double strands of duplex DNA, which allows the strands to pass through one another, thus altering the DNA topology. Irinotecan (CPT11) and topotecan are known TOP1-targeting agents in clinical use [2] . Drugs that target TOP2α can be divided into two broad classes. The first class is termed TOP2α poisons. Use of such an agent leads to increased levels of TOP2α and DNA complexes. These drugs generate DNA lesions that include DNA strand breaks and protein covalently bound to DNA. TOP2α trapping and enzymemediated DNA damage are believed to be the cause of cell death [3] . Active TOP2α poisons such as doxorubicin, etoposide, and mitoxantrone belong to this class [4] [5] [6] . Resistance to these drugs is frequently associated with reduced expression of TOP2 isomers [7] . The second class is called a catalytic inhibitor compound (CIC). They inhibit TOP2α enzyme activity, but do not increase the levels of TOP2α and DNA covalent complexes usually. TOP2 CICs are believed to kill by depriving the essential enzyme activity of TOP2α [8] .
YM155 is a small molecule inhibitor that emerged from a drug screen using a construct that consisted of a survivin promoter and a luciferase reporter and was described as a survivin suppressant [9] . It showed potent activities against a variety of cancer cells including non-small cell lung, breast, prostate, and non-Hodgkin's lymphoma in-vitro and in animal models (for a review, refer to Rauch et al. [10] ). Despite its potency and good tolerability in preclinical and early clinical studies, several phase II studies using YM155 either alone or in combination with other chemotherapy agents yielded negative results [11] [12] [13] [14] . This failure may be a consequence of incorrect understanding of the molecular target and the resultant absence of patient population stratification. Clinical trials of anticancer drugs conducted in a patient population with a mixed genetic background often end up in failure [15] .
Despite widespread acceptance as a survivin suppressant, YM155 efficacy does not correlate with survivin levels. In the Merkel cell model [16] , YM155 was cytostatic instead of inducing apoptosis, which most of us would expect from a survivin suppressant. Interestingly, YM155 induced DNA damage and triggered DNA damage checkpoint signaling in our previous studies and others [17, 18] . The number of mutations in the YM155 resistant clones was ∼ 10-fold of other drug-resistant clones, suggesting that YM155 is highly mutagenic [19] . Analyses of mutations using a technique combining the next-generation sequencing with a CRISPR/ Cas9-based method failed to show a specific resistance mechanism possibly because of the large number of mutations YM155 induced. Interestingly, a genome-wide insertional mutagenesis screening using the KBM7 near the haploid human cell line showed that YM155 sensitivity depended on the expression of a solute carrier SLC35F2, which is highly expressed in a variety of cancer cell lines [20] .
Here, we show here that YM155 is a TOP inhibitor. DNA TOPs play important roles in various cellular processes. Inhibition of DNA TOP by YM155 could explain all phenomena observed during YM155 treatment. These include stalled DNA replication, decreased transcription, problems in mitosis, and defects in DNA repair in addition to DNA damage, which triggers the DNA checkpoint signaling. This provides a unified mechanism of action for YM155 while being in contrast to reports defining YM155 as a DNA intercalator [19, 20] . Simultaneous elucidation of the molecular target of YM155 and marker for efficacy, when validated, will hopefully rejuvenate YM155 clinical research and lead to eventual use of this drug in cancer treatment. It is unknown at present whether TOP inhibitors that are not TOP poisons might be active anticancer agents [8] . It is hoped that YM155 may become the first non-TOP poison in the clinical arena.
Materials and methods
Cell line, antibodies, and chemicals H1299 was purchased from the American Type Culture Collection and cultured in RPMI 1640 (Invitrogen, Carlsbad, California, USA) with 5% FBS (Hyclone, Logan, Utah, USA) at 37°C in 10% CO 2 . YM155 (S1130) and BI6727 (S2235) were purchased from Selleck Chemicals (Houston, Texas, USA). L-Mimosine, nocodazole, and 5-bromodeoxyuridine (BrdU) were products of Sigma-Aldrich (St. Louis, Missouri, USA). All antibodies for western blot analysis of cell cycle proteins were from Cell Signaling Technology (Beverly, Massachusetts, USA) including p21, p27, cyclin D1, Cdt1, cyclin A1, cyclin E1, proliferating cell nuclear antigen, and cyclin B1. Actin B antibody was purchased from SigmaAldrich. Anti-BrdU-APC was from eBioscience (San Diego, California, USA). HU331 was purchased from Abcam (Cambridge, Massachusetts, USA) (ab120922).
Cell cycle analysis and BrdU incorporation
Cell cycle was synchronized with either BI6727 or mimosine or nocodazole. Analyses were carried out using standard flow cytometry procedures following either propidium iodide staining alone [21] or together with BrdU incorporation. These cells were then stained with anti-BrdU-APC (eBioscience) as described previously [22] . Cells were analyzed using an LSRII flow cytometer. All flow cytometry data were analyzed using FlowJo software (Tree Star, Ashland, Oregon, USA).
Western blot
Proteins were isolated using standard procedures. Wholecell lysates containing 50 μg of proteins were separated by SDS-PAGE and immunoblotted with the following specific antibodies. Antibodies were used at 1 : 1000 as recommended by the manufacturer. Immunoblot was performed using standard protocols as described previously.
Viscometric titrations
Viscometric titrations were performed using a CannonUbbelohde semimicroviscometer (Vernon Hills, Illinois, USA), submerged in a water bath to maintain a constant temperature at 25°C as described previously [23] . The concentration of calf thymus DNA was measured spectrophotometrically and a 10 ml, 200 μmol/l (bp) solution of calf thymus DNA in Tris-HCl buffer (50 mmol/l TrisHCl, 100 mmol/l NaCl, and 1 mmol/l EDTA at pH 7.4) was used in viscometric titrations. Incremental addition of compounds with thorough mixing from concentrated stock solutions was used to titrate the DNA in the viscometer. The final volume did not increase more than 2% of the initial volume during the titration. Each addition was followed by an equilibration time of 20 min before the flow times were measured. The intrinsic viscosities were proportional to the flow times of the solutions and calculated as given in the literature [24] .
where η is the viscosity of the solution containing ligandbound DNA, η o is the viscosity of the solution containing free DNA, t is the flow time of solution containing ligandbound DNA, t o is the viscosity of the solution containing the free DNA, and t b is the flow time of buffer.
Circular dichroism spectroscopy
Circular dichroism (CD) experiments were conducted on a Jasco J-810 CD spectrometer in a 1-cm quartz cell at 25 o C. The hairpin duplex DNA (5 µmol/l) sequence in buffer (50 mmol/l Tris-HCl, 100 mmol/l NaCl, 1 mmol/l EDTA, pH 7.4) was added to the cell before the experiment and then the compound was added to the hairpin DNA solution and incubated for 10 min to achieve equilibrium. For each titration point, four spectra were averaged from 500 to 220 nm with a scan speed of 50 nm/min and a response time of 1 s. Buffer-subtracted graphs were created using the Kaleidagraph software (Reading, Pennsylvania, USA).
Structural model calculation methods
Molecular modeling studies were initiated with a conformational analysis of the tested compound with a molecular mechanics force field approximation level using the Spartan 10 software package (Wavefunction Inc., Irvine, California, USA) [25] . The software package was used to optimize the final geometry using ab-initio calculations with density functional theory, B3LYP at the 6-31G* approximation level.
Assay for TOP1, TOP2α, and Escherichia coli gyrase TOPs and bacterial gyrase assay were performed using the TOPOGEN enzyme kit (TG1018, TG1001, and TG2000G1) (Topogen Inc., Buena Vista, Colorado, USA). The TOP1 assay was described previously [26] . Briefly, For the TOP2α assay [27] , reaction mixtures that contained 10 × reaction buffer, 4 U/reaction of purified human TOP2α, 200 ng of kinetoplast DNA (kDNA), VP16 (control), or various concentrations YM155 (0-100 μmol/l) were set up and incubated at 37 o C for 30 min. The reaction was stopped and treated with protein kinase at 37 o C for 15 min, phenol extracted before dividing into halves, and loaded onto 1% agarose gel with or without EtBr. The gels were run at 50 V for 45-60 min before photography after staining when needed.
E. coli bacterial gyrase assays [28] were performed in a mixture containing 8 U of purified bacterial gyrase, 5 × reaction buffer, 200 ng of relaxed pHOT, HU331, or YM155 at various concentrations at 37 o C for 30 min. The reaction mixtures were stopped, treated with protein kinase, and extracted by the phenol before loading. They were run under the same condition as above before pictures were taken.
Immunofluorescence microscopy
The immunofluorescence staining was performed as described previously [29] . Briefly, cells were plated onto poly-L-lysine-treated glass coverslips and cultured for 24 h in RPMI 1640 medium with 10% FBS and penicillin-streptomycin to allow cells to adhere to the substrate. Cells were radiated with 2 Gy in a radiator before the cultural medium were changed to RPMI 1640 with either dimethyl sulfoxide (DMSO) or YM155 (0 h). At 0, 2, 4, and 12 h, coverslips were rinsed twice with PBS for 5 min. Cells were fixed in a fixative solution, permeabilized with 0.1% triton in PBS for 10 min at room temperature, and blocked with 3% ovalbumin in PBS (blocking solution). Primary antibodies (γH2AX from Cell Signaling Technology) and RAD51 (Novus Biologicals, Littleton, Colorado, USA) were diluted at 1 : 200 (or as recommended by the manufacturer) in blocking solution and incubated overnight at 4°C. Cell were rinsed three times with PBS for 5 min and incubated for 30 min at 37°C with the respective secondary antibodies diluted 1 : 200 in blocking buffer. Confocal images were obtained using an Axiovert 200M Zeiss microscope equipped with Zen 2009 software (Carl Zeiss Microscopy, Gottingen, Germany). Numbers of foci per cell were counted using Image J (NIH, Bethesda, Maryland, USA) software. Data analysis was carried out and statistical differences were determined with Student's t-test using the Excel software (Excel, Seattle, Washington, USA).
Results
YM155 suppresses DNA replication, and arrests cell cycle at the G1/S or G2/M When unsynchronized H1299 cells growing in the log phase were analyzed for cycle distribution, the majority of them were found in G1 with a 2N DNA content. When they were treated for 24 h with BI6727 (volasertib, a small molecule PLK1 inhibitor), they arrested with a 4N content at M (polo arrest with 4N DNA content) [30] . However, the cell cycle distribution did not change when they were treated with either YM155 alone or in combination with BI6727 (data not shown). When cells arrested at the M phase with BI6727 for 24 h were released in medium containing DMSO, YM155, BI6727, or YM155 plus BI6727, cells in the DMSO group restarted the cell cycle, divided with a significantly larger G1 peak after 4-8 h and G1 and S peaks after 24 h, indicating successful progression into the S phase. Cells in BI6727 (BI6727 added to RPMI 1640 fresh at the same concentration used to arrest the cells at M) remained predominantly at M after 24 h. Interestingly, we observed a sizable 8N peak in these cells, suggesting that some of these cells have come out of the M phase and went on to replicate their DNA before successful cytokinesis as reported previously [31] . When these cells were grown in medium containing YM155 alone, slightly less than half of all cells could progress into the G1 phase from M similar to the DMSO group, indicating that these cells had no major problems transitioning from M to G1. The remaining cells, however, remained in M, suggesting that these cells had problem moving forward, which is consistent with defects in chromosomal separation (see below). Noticeably, also, cells grown in both BI6727 and YM155 had no 8N peak at all, suggesting that cells could not replicate their DNA in the presence of YM155 (Fig. 1a ). All these above results suggested that YM155 arrested the cell cycle at the G1/S boundary or G2/M as they could not finish DNA replication and may have problems in separating their chromosomes. This could occur when TOP activity is impaired [32, 33] . To test this hypothesis more vigorously, we synchronized H1299 cells by treating with mimosine for 24 h, which arrests cells in the G1/S border [34] . These cells were shifted to medium containing either DMSO or YM155 after mimosine was washed out. Cell cycle profile and DNA replication were followed by BrdU incorporation at 4, 8, and 24 h. Although the percentage of S phase cells increased by 26.6 and 54.3% after 4 and 8 h, respectively, in the DMSO group, the S phase cells in the YM155 group showed only a modest increase to 16.3 and 19.2% after 4 and 8 h, respectively. Even after 24 h, there was only a 23% increase, consistent with a blockage in the G1/S phase in the YM155 group (Fig. 1b) . As some cells blocked with mimosine might had already entered into the S phase, we further experimented with cells arrested at mitosis by nocodazole, which arrests cells at G2/M by inhibiting microtubule polymerization [35] . When these cells were shifted from nocodazole containing medium to one containing DMSO or YM155, cells in the DMSO group progressed synchronously to G1 after 8 h. These (Fig. 1a) , only a small proportion of cells failed to exit M completely after 24 h (Fig. 1c) ; the majority of cells experienced no problem in M/G1 transition possibly because of the later arrest point of nocodazole compared with BI6727. TOPs are presumably no longer needed. At the protein levels, western blot analyses of nocodazole arrested cells released into YM155 were consistent with the fact that YM155 prevented progression of cells into the S phase (Fig. 1d) . Cyclin A1 expression, which correlates with the initiation of the S phase, did not accumulate significantly at 24 h after nocodazole-treated cells were released into medium containing YM155, suggesting that these cells were not progressing into the S phase. In addition, the expressions of p21, p27, proliferating cell nuclear antigen, and cyclin E1 were not affected, but YM155 prevented cyclin D1, Cdt1, and cyclin B1 from accumulating again after the first decrease. 
YM155 does not form a complex with free DNA
The positively charged planar scaffold of YM155 would also favor intercalation with DNA. Therefore, it is possible that YM155 functions as a DNA intercalator and introduces positive supercoils in the DNA. The DNA is subsequently relaxed by TOP 1, resulting in DNA damage and checkpoint signaling like a typical DNA intercalating agent EtBr. We therefore decided to test whether YM155 can function as a DNA intercalator in a viscosity study using EtBr as a control. As shown in Fig. 2a , increasing concentrations of EtBr binding to DNA clearly increased the viscosity of the EtBr-DNA complex, which plateaued after the ratio reached 1 : 5. YM155, however, failed to increase the viscosity of the DNA even when the YM155 concentration reached up to 100 μmol/l. Molecular interactions can be detected by studying CD spectroscopy. We also investigated whether YM155 behaves like a DNA chelator to induce circular dichoism. Normally, DNA minor groove binders always induce a large induced CD signal, whereas intercalators yield a more varied response. However, increasing the concentration of YM155 up to 60 μmol/l failed to induce a CD spectral change (Fig. 2b) , suggesting that YM155 is not a significant minor groove binder or an intercalator.
To back up our conclusion (that YM155 is not a minor groove binder), we conducted molecular modeling experiments. Not surprisingly, we found that the compound phenyl and alkyl substituents are out of the plane of the larger ring system and block both intercalation and minor groove binding of the compound to DNA (Fig. 2c-f) . Therefore, our data are not consistent with the hypothesis that YM155 functions as a DNA chelator in contrast to previous publications [19, 20] .
YM155 inhibits TOP2α and TOP1 activity
TOPs alter DNA topology, adjust DNA supercoiling by introducing single-strand (TOP1) and double-strand (TOP2) DNA breaks, before resealing them during DNA replication, transcription, DNA repair, recombination, and chromosomal separation. YM155 exposure led to inhibition of DNA replication (above) and transcription suppression and possibly chromosomal separation (above). We thus tested whether YM155 might interfere with TOP(s) function. We first assayed TOP 1 plasmid cleavage activity in the presence of YM155 first. In the EtBr gel (Fig. 3a) , TOP1 could cut the supercoiled DNA (form I, lane 1) and lead to the appearance of open circular DNA (relaxed DNA, form II, lane 2). CPT, a well- Fig. 3b ). It should be pointed out that the distribution of topoisomers was shifted in lane 11 (parenthesis on right). To characterize the interaction between TOP2α and YM155, we carried out a TOP2α assay. In the EtBr gel assay (Fig. 3c) , TOP2α could convert catenated kDNA (did not enter into the gel because of size, lane 1) into decatenated DNA (lane 3). The presence of a known TOP2α poison etoposide (VP16) led to the appearance of linear DNA complex (lane 2). YM155 did not increase the amount of the linear DNA complex as did etoposide. Instead, it significantly inhibited the decatenation of kDNA (lane 11, parenthesis). This strongly suggests that YM155 is suppressing the function of the enzyme. The same scenario was true when the assay was performed in non-EtBr (Fig. 3d) . YM155 was hindering the decatenation process, generating less decatenated DNA (lane 11, parenthesis).
HU331 is a well-characterized TOP2α ATPase inhibitor [36] . In further studies, it did not inhibit TOP1 activity when used up to 100 μmol/l level (Fig. 4a) . Consistent with previous studies, HU331 inhibited decatenation of TOP2α in a dose-dependent manner, with effects becoming obvious at 100 μmol/l and reaching the maximum at 500 μmol/l (Fig. 4c) . The E.coli gyrase activity was also not affected (Fig. 4e) . Although E. coli gyrase activity was not affected by YM155 (Fig. 4f) , YM155 inhibited TOP2α in a dose-dependent manner (Fig. 4d) . Compared with HU331, the activity was more potent, which became obvious when 3.0 μmol/l of YM155 was present. In addition, YM155 also inhibited TOP1 when the concentration reached 30 μmol/l (Fig. 4b) . 
YM155 delays DNA repair
TOPs are involved in DNA repair. Given that our results above were consistent with inhibited TOP activity in the presence of YM155, we hypothesized that DNA repair was compromised in the presence of YM155. Ionized radiation results in DNA double-strand breaks (DSBs). Active DSBs trigger phosphorylation of H2AX (γH2AX), forming foci in the nucleus. The persistence of foci signals continued in the presence of DSBs. However, RAD51 forms foci as the homologous recombination repair mechanism starts to repair damaged DNA until the repair is complete. Two, six, and twelve hours after H1299 cells were radiated with 2 Gy X-ray, cells were processed for γH2AX and RAD51 staining. In the absence of YM155, γH2AX foci (green) peaked 2 h later and started to fade below the initial level after 12 h. In the presence of YM155, the immunofluorescence continued unfaded, suggesting persistent high levels of DNA damage. RAD51 foci (red) peaked robustly after 12 h in the presence of DMSO after DNA damage. However, significantly fewer RAD51 foci were present in these cells in the presence of YM155, suggesting inhibited DNA repair foci formation in these cells (Fig. 5a ). Counting for foci formation for γH2AX and RAD51 (Fig. 5b) was consistent with the hypothesis that YM155 suppressed DNA repair while inflicting constant DNA damage.
Discussion
Identifying the mechanism of action of a new molecular entity poses a major challenge in drug discovery as well as in chemical biology research [37] . When the target of a drug is unknown, it is difficult to select the right type of cancer to treat, nearly impossible to improve its efficacy, or reduce unanticipated toxicity. A rationale combination with other drugs is not possible. The cost of the abandoning drugs is contributing toward the rapid increase in the drug price at 7.3% annually according to the 2003 publication [38] .
Here, we show that YM155 targets DNA TOPs. The use of YM155 clearly blocked progression through S and M phases (G1/S, G2/M arrest). YM155 also induced DNA damage, checkpoint signaling, and caused a delay in DNA DSB repair. In-vitro assay of TOP activity showed that YM155 potently suppressed TOP2α's ability to decatenate kDNA and TOP1 cleavage of plasmid DNA. This explains why the luciferase activity under the control of a survivin promoter was severely decreased in the original discovery screening since YM155 is expected to reduce DNA transcription markedly when both TOP1 and TOP2α activity are compromised. This also potentially explains why YM155 GI50 is at nanomole level in vivo, whereas a micromole concentration was needed to completely block the TOP activity in our study. As a comparison, YM155 shown here is at least as good as if not more potent than etoposide in previous publications (the average concentration of etoposide used was 50 μmol/l).
In the presence of YM155, DNA repair was defective. There were fewer RAD51 repair foci observed with YM155 (above). In addition to suppressed TOP activity itself, inability to enter into the S phase is believed to have contributed since homologous repair occurs predominantly during the S phase. This is consistent with previous reports that YM155 boosted the effects of cisplatin [39] and radiation therapy [40] in earlier studies. Our work thus unifies studies related to the mechanism of action of YM155 and suggests TOP but not survivin as the molecular target of YM155. The proposed mechanism of action for YM155 is illustrated in Fig. 6 . This study also contrasts earlier studies claiming YM155 as a DNA intercalator [20] .
As stated earlier, TOP2 targeting agents fall into two categories: the poisons and the CICs. It is believed that TOP2α poisons effectively block DNA replication and transcription, leading to an increase in the levels of DSBs and protein covalently bound to DNA, resulting in an increase in enzyme-mediated DNA damage. However, CICs, on short-term exposure, do not stimulate enzymemediated DNA damage and they do not induce DNA damage response [41] , except long term, although most CICs studied so far are not specific, except one [42] , and are very weak compounds. It is not clear here exactly how YM155 targets TOP1 and TOP2α, and YM155 could be a competitive ATPase inhibitor. Alternatively, YM155 could saturate DNA binding sites within TOPs; thus, these enzymes lose the ability to bind DNA. As undecatenated DNA is believed to be monitored by the DNA damage/ unreplicated DNA checkpoint [43] , YM155 exposure is expected to cause DNA damage.
In clinical oncology, two things are crucial for bringing a drug to the clinical arena. One is having a clear molecular target and another is knowledge of the marker for sensitivity/resistance. Therefore, it becomes much easier when a molecular marker that is both prognostic and predictive of response is known. Now that YM155 has a well-defined molecular target (as TOP) and SLC35F2 looks like a promising marker for YM155 sensitivity/ resistance, rationale combination may start here. For example we may combine the PLK1 inhibitor with YM155 in lung cancer as PLK1 also participates in the repair of TOP2α − mediated DNA damage [17] . In a preselected patient population, the combined use of two or more drugs that act synergistically in those cancers highly expressing TOP2α are expected to make a huge difference in the results. So far, preclinical data predict that YM155 would be useful in patients with breast, prostate, lung cancer, and mantle cell lymphoma [44] , in which TOP poison have made important contributions toward treatment. Interestingly, anaplastic thyroid cancer that expresses TOP2α five-fold higher than differentiated thyroid cancer (personal data) was highly sensitive to YM155 [45] . Uncertainty of the molecular target and the lack of a rationale combination in an unselected population were likely responsible for the failure of YM155 in recent clinical trials.
